Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib with Docetaxel and Prednisone in mCRPC
NCT00527124Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2007
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib in prostate cancer (PCa), sponsored by National Cancer Institute. Started Nov 2007; status: terminated.
02
Drugs
cediranib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00527124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00527124.